VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.
Patients were divided into two groups, with a baseline visual acuity of 20/50 or worse or 20/40 or better, to evaluate visual acuity and anatomic outcomes after treatment with both doses of aflibercept.
“The key findings from our research showed that, regardless of baseline visual acuity, both aflibercept 8 mg or aflibercept 2 mg were very effective and comparable in improving visual acuity and reducing retinal thickness,” Do said.
Collapse
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts